Joshua L Lee1,1, Lauren E Haydu2,3,2,3, John F Thompson2,3,2,3, Rachael L Morton1,4,1,4. 1. School of Public Health, Sydney Medical School, The University of Sydney, Sydney, Australia. 2. Melanoma Institute Australia, North Sydney, Australia. 3. Sydney Medical School, The University of Sydney, Sydney, Australia. 4. Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Headington, Oxford, UK.
Abstract
AIM: This study aims to determine whether socioeconomic status (SES) is associated with participation in melanoma clinical trials. PATIENTS & METHODS: A retrospective, single-center observational study was conducted at the Melanoma Institute Australia. Factors affecting clinical trial participation were assessed using logistic regression. RESULTS: Of 9074 patients, 2304 (25%) participated in a clinical trial. Multivariate analysis indicated males compared with females (odds ratio [OR]: 1.18; 95% CI: 1.07-1.30) and patients with American Joint Cancer Committee stage II or III disease (but not stage IV disease) were more likely to participate in trials than patients with stage I disease (OR: 2.81 [95% CI: 2.50-3.16] and OR: 4.55 [95% CI: 3.91-5.30], respectively). SES did not affect trial participation. CONCLUSION: Our data suggest that SES is not a significant predictor of melanoma clinical trial participation when adjusted for other factors.
AIM: This study aims to determine whether socioeconomic status (SES) is associated with participation in melanoma clinical trials. PATIENTS & METHODS: A retrospective, single-center observational study was conducted at the Melanoma Institute Australia. Factors affecting clinical trial participation were assessed using logistic regression. RESULTS: Of 9074 patients, 2304 (25%) participated in a clinical trial. Multivariate analysis indicated males compared with females (odds ratio [OR]: 1.18; 95% CI: 1.07-1.30) and patients with American Joint Cancer Committee stage II or III disease (but not stage IV disease) were more likely to participate in trials than patients with stage I disease (OR: 2.81 [95% CI: 2.50-3.16] and OR: 4.55 [95% CI: 3.91-5.30], respectively). SES did not affect trial participation. CONCLUSION: Our data suggest that SES is not a significant predictor of melanoma clinical trial participation when adjusted for other factors.
Entities:
Keywords:
clinical trials; equity; melanoma; participation; socioeconomic status
Authors: Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245
Authors: Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Margaret M Byrne; Stacey L Tannenbaum; Stefan Glück; Judith Hurley; Michael Antoni Journal: Med Decis Making Date: 2013-07-29 Impact factor: 2.583